DexCom, Inc. (NASDAQ:DXCM) Chairman Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $55.91, for a total value of $559,100.00. Following the transaction, the chairman now directly owns 484,559 shares in the company, valued at $27,091,693.69. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of DexCom, Inc. (NASDAQ DXCM) opened at $57.13 on Wednesday. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $4,983.03, a P/E ratio of -100.23 and a beta of 0.21. DexCom, Inc. has a 52-week low of $42.62 and a 52-week high of $86.32.
A number of research firms recently weighed in on DXCM. BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. BMO Capital Markets increased their price objective on DexCom to $74.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Northland Securities downgraded DexCom from a “market perform” rating to an “under perform” rating and set a $85.00 price objective for the company. in a research note on Thursday, January 4th. Jefferies Group increased their price objective on DexCom from $58.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, December 22nd. Finally, ValuEngine downgraded DexCom from a “hold” rating to a “sell” rating in a research note on Thursday, February 8th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $67.44.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.